title: Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
authors.forename: Christine S
authors.initials: CS
authors.lastname: Paine
mesh_terms: D016363:Antitrust Laws; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence*; D016568:Drugs, Generic; D004465:Economic Competition / Q000331:legislation & jurisprudence; D017850:Economics, Pharmaceutical; D006801:Humans; D010330:Patents as Topic / Q000331:legislation & jurisprudence*; D014481:United States; D014485:United States Federal Trade Commission; D014486:United States Food and Drug Administration
chemical_list: D016568:Drugs, Generic